Intelligent Micro/Nanorobots for Targeted Interventional Therapy: From Bench to Clinic
Zirui Zhang et al. reviewed the application and challenges of mobile nanomachines in interventional therapy. By converting exogenous energy, including chemical, magnetic, optical, and ultrasonic sources, into mechanical forces, micro/nanorobots (MNRs) enable precise actuation at unprecedented scales. Evolving far beyond traditional drug delivery, these
Zirui Zhang +5 more
wiley +1 more source
Epicutaneous and Drug Provocation Testing in Severe Cutaneous Adverse Reactions: A 20-Year Single-Centre Experience. [PDF]
Chadli Z +8 more
europepmc +1 more source
Pancreatic adenocarcinoma (PAAD) remains highly lethal with limited treatment options. This study demonstrates that coixenolide, a bioactive compound from Coix lacryma‐jobi L. and a key component of the clinically approved Kanglaite injection, exhibits enhanced antitumor efficacy in high‐fat diet (HFD)‐induced obese mice bearing PAAD tumors compared to
Kaidi Chen +20 more
wiley +1 more source
Metformin combined with progesterone improves efficacy and reduces adverse reactions in early endometrial cancer. [PDF]
Li J, Hou Y, Liao D.
europepmc +1 more source
Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system. [PDF]
Ding P, Luo Q, Cao L.
europepmc +1 more source
Knowledge, attitudes, and practices of chemotherapy adverse reactions and care among patients with gastrointestinal lymphoma. [PDF]
Li P +6 more
europepmc +1 more source
The impact of sarcopenia on short-term efficacy, toxic and adverse reactions, and prognosis in patients with non-small cell lung cancer undergoing concurrent chemoradiotherapy. [PDF]
Yuan Y +6 more
europepmc +1 more source
Adverse Reactions Following Intradermal Injection of Exosome-Based Formulations: A Case Series. [PDF]
Park KY.
europepmc +1 more source
Analysis of anticancer drug associated adverse reactions in depressive patients from vigibase. [PDF]
Chretien B +5 more
europepmc +1 more source

